Lymphomas Overview
|
Background:
"Primary
Mediastinal B-cell lymphoma (PMBL/PMBCL)) is a diffuse large B-cell lymphoma
that arises in the thymus and mainly affects young adults.
Molecular diagnosis of Primary Mediastinal B Cell Lymphoma
has identified it as a clinically favorable subgroup of Diffuse Large B Cell Lymphoma
related to Hodgkin Lymphoma 2
Gene expression profile in PMBCL:
Primary mediastinal large B cell lymphoma (PMBCL) has been thought of as a
special subtype of DLBCL. Its distinct clinical presentation in younger
patients with a female predominance has led to the suspicion that it constitutes a unique entity. However, reliable distinction from DLBCL has
remained elusive.
Gene expression analysis has settled the question and provided surprising
insight into this lymphoma's unique biology, including similarities to
Hodgkin lymphoma5. Based on a core cluster signature of 46 specific genes,
35 of which are relatively overexpressed in PMBCL and 11 in DLBCL, PMBCL can
be quite accurately distinguished from all other types of large B cell
lymphomas.
This unique gene expression signature includes a number of regulators of T
cell activation, but, even more surprisingly, over one-third of the genes
that are more highly expressed in PMBCL than in other large B cell lymphomas
are also characteristically over-expressed in cells from putative
(regarded as) Hodgkin
lymphoma cell lines.
Of particular note is the overexpression of several genes associated
with nuclear factor κ B (NFκB), revealing a pivotal role for this gene complex
and suggesting possible points of attack for future therapeutic
agents.
In the case of PMBCL, the application of gene expression profiling has
provided not only improved accuracy of diagnosis and provocative suggestions
for possible targets for new therapeutic agents, but also intriguing linkages to Hodgkin lymphoma.
SOURCE: Improving Diagnosis and Treatment of Lymphomas with Gene
Expression Profiling, Joseph M. Connors, M.D. - hematology.org
"Major new insights into the biology of lymphomas have resulted
from the use of microarray gene expression technology to elucidate
their underlying biology and to identify novel pathways for
therapeutic intervention."
____________________________________________
Incidence:
Mediastinal large B-cell lymphoma is a rare form of
non-Hodgkin's lymphoma, accounting for about 1 in 50 of all cases,
"In
REAL classification PMBL is considered a variant of diffuse large B
cell lymphoma." "PMBL accounts for about 2 percent of all
non Hodgkins lymphoma." 1
Because of its skewed age distribution, PMBL accounts for a
much higher proportion of both younger patients and those undergoing
autologous transplantation. Uncertainty remains regarding the
management of this disorder." 7
____________________________________________
Diagnosis:
To make an accurate diagnosis of lymphoma, a
biopsy must be performed by the surgical removal (resection) of a
lymph node. If the lymph
nodes within the mediastinum are the only ones affected, the biopsy is
likely to be taken during a procedure known as a mediastinoscopy.
A series of tests will then
be performed to determine the characteristics of the cells. If a
malignancy is determine, these characteristics will allow your doctors
to determine the appropriate treatments to use when needed.
Specific markers:
____________________________________________
Common signs
and symptoms:
 |
breathlessness* |
 |
cough or chest pain* |
 |
fatigue |
 |
loss of appetite |
 |
enlarged lymph nodes - painless swelling in the
neck, armpit or groin - often in more than one group.. |
Other symptoms may include night sweats, unexplained
high temperatures and weight loss. These are known as B
symptoms.
____________________________________________
Resources:
-
Primary mediastinal B cell lymphoma (PMBL) in two sisters
Year: 2002
Abstract No: 2646
-
Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma -
jem.org 9_15_03
-
Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma -
jem.org 9_15_03
-
Primary Mediastinal Large B Cell Lymphoma: Elucidating
Optimal Therapy and Prognostic Factors; an Analysis in 141
Consecutive Patients Treated at Memorial Sloan Kettering from
1980-1999. Session Type: Oral Session - ASH
2004
Lymphomas: Non-Hodgkin Lymphoma - Medscape
(free login req.)
About Mediastinal large B-cell lymphoma - Cancerbackup
About Mediastinal large B-cell lymphoma - Emedicine
____________________________________________
Treatment:
TOPIC SEARCH ASCO
| Medscape |
PubMed
Some patients with
early-stage primary mediastinal DLBCL (PMBCL), however, may require
involved-field radiation after chemotherapy.
In a study of 50 patients with untreated PMBCL who received MACOP-B
(methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide,
vincristine, prednisone, and bleomycin) followed by radiation, 66% had
a persistently positive gallium scan after chemotherapy alone,
suggesting active disease.136
However, treatment of PMBCL with other regimens that do not include
involved-field radiation, such as ACVBP and DA-EPOCH, have yielded
good results in PMBCL.71,135 Furthermore, rituximab has
improved the outcome in DLBCL.79 Hence, it is reasonable to
limit involved-field radiation to those patients with persistently
positive PET scans after such treatments. - Medscape
06/07/2006
 |
Primary mediastinal large B-cell lymphoma: optimal therapy and
prognostic factor analysis in 141 consecutive patients treated at
Memorial Sloan Kettering from 1980 to 1999. Br J Haematol. 2005
Sep;130(5):691-9. PMID:
16115124
We conclude: (i) dose-dense chemotherapy with NHL-15 may be
superior to CHOP for PMLBL; (ii) The impact of consolidative
radiotherapy requires randomized controlled trials; (iii) The
age-adjusted IPI did not predict survival in this analysis; (iv)
high-dose chemotherapy/ASCT should be reserved for upfront
anthracycline-based therapy failure or in clinical trials for
high-risk patients.
|
 |
Primary mediastinal large B-cell lymphoma (PMLBCL): long-term
results from a retrospective multicentre Italian experience in 138
patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer. 2004 Jan
26;90(2):372-6. PMID:
14735179
In our experience, MACOP-B/VACOP-B appears to positively influence
OS and EFS in patients affected by PMLBCL, as compared to CHOP.
Consolidation IF-RT on mediastinum further improves the outcome of CR
patients.
|
 |
Combined therapy in the treatment of primary mediastinal B-cell
lymphoma: conventional versus escalated chemotherapy.
Ann Hematol. 2002 Jul;81(7):368-73. Epub 2002 Jun 21. PMID:
12185505
We feel that patients with PMBCL should be treated with more
intensive, but not myeloablative chemotherapy, followed by adjuvant
radiotherapy to achieve an improvement in outcome in this setting of
patients. Patients with pleural or pericardial effusion are considered
at high risk for failure with the actual programs of treatment and
probably will be considered for experimental therapeutic approaches.
|
____________________________________________
Clinical Trials:
Lymphoma-specific clinical trials by:
All
for this type
Treatment
type ...includes links to related
PubMed abstracts
Other
criteria ... includes filters for age, frontline,
grade, phase, stage, and refractory disease
By
State & Country
____________________________________________
Research News:
 |
..
|
|